# Frequently asked questions about melanotan: answered from the published literature

> melanotan frequently asked questions: mechanism, dosage, safety, Phase I data, PT-141 comparison, and the regulatory record. Direct answers from the published literature.

## Compound Basics

**What is melanotan?**
melanotan refers to two synthetic peptide analogs of alpha-MSH — Melanotan I (afamelanotide) and Melanotan II — developed at the University of Arizona. Both bind melanocortin receptors to trigger eumelanin synthesis [1][2].

**What is the difference between Melanotan I and Melanotan II?**
MT-I (afamelanotide) is a linear 13-amino-acid analog with high MC1R selectivity; MT-II is a cyclic 7-amino-acid analog with broader MC1R/MC4R/MC3R activity. MT-I is EU/FDA-approved for EPP; MT-II has no approved indication [2].

**Where are melanotan injections derived from or made out of?**
Both analogs are fully synthetic peptides, not derived from biological sources. Manufactured via solid-phase peptide synthesis from standard amino acid precursors [1].

**What is melanotan 2 used for in research?**
Four research domains: pigmentation/melanogenesis [3], erectile dysfunction [5][6][7], appetite/metabolism [8][9][10], and peripheral nerve regeneration [21].

## Mechanism and Pharmacology

**How does melanotan work in the body?**
Binds melanocortin receptors on melanocytes, triggering eumelanin production via the cAMP/PKA/CREB/MITF/tyrosinase cascade [4]. MT-II's MC4R binding drives appetite suppression and pro-erectile signaling [5][8].

**Does melanotan work without sun exposure?**
Phase I data (Dorr 1996) showed measurable pigmentation increases without UV in 2 of 3 subjects [3]. MT-II activates MC1R directly.

**Does Melanotan 2 make your hair darker?**
Mechanistically plausible (MC1R is expressed in hair follicle melanocytes), but no controlled clinical study data exists for MT-II-induced hair color change in humans.

**Does melanotan cause fat loss?**
Rodent ICV studies demonstrated adiposity reduction via MC4R. Chronic central MTII over 40 days reduced intra-abdominal fat 35–55% in aged rats [9]. No controlled human data exists for weight or fat-mass reduction from MT-II.

## Safety and Adverse Events

**Does Melanotan 2 affect the kidneys?**
Two published case reports: 27 mg cumulative MT-II over 6 months produced renal infarction (~50% of kidney) [11]; a single 6 mg injection produced rhabdomyolysis (CPK 17,773 IU/L) and AKI requiring 3-day ICU admission [12].

**Can melanotan affect the appearance of moles?**
Yes — documented in published case reports [13][14] and regulatory safety notices. A 25-year-old developed dysplastic nevi with severe dysplasia; a 16-year-old with FAMMM syndrome developed multiple dark nevi that partially reversed after cessation.

**Is melanotan (afamelanotide) or Melanotan II truly dangerous?**
MT-I (afamelanotide/Scenesse) has an established safety record in regulated EPP trials. MT-II: case reports document nausea [3], mole changes [13][14], renal infarction [11], rhabdomyolysis with AKI [12], and mucosal malignant melanoma associated with nasal spray use [25].

**Does Melanotan 2 lower testosterone?**
No controlled trial data. A rat study found MT-II did not affect NPY-driven suppression of the gonadotropic axis (LH) or somatotropic axis (GH) [22].

## Duration and Dosing

**How long does tan from melanotan last?**
4–6 weeks measurable pigmentation post-cessation in Phase I trials [3].

**Does melanotan permanently tan skin?**
No. Research does not support permanent pigmentation. Case reports confirm reversal after cessation [14][24].

**How long does it take for melanotan to start working?**
Objective colorimetric increases measurable at 2–4 weeks of daily subcutaneous dosing in Phase I [3]. ED effects observed acutely within hours of a single injection [5].

## Related Compounds and Research Context

**What is the difference between melanotan and PT-141 (bremelanotide)?**
PT-141 (bremelanotide) is a direct chemical descendant of MT-II — modified for MC4R activity with reduced MC1R pigmentation effect. PT-141 received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women. MT-II has no FDA-approved indication [19].

**Does Melanotan II increase testosterone?**
No controlled human data. MT-II's MC4R agonism drives pro-erectile signaling via NO release — not through gonadal androgen pathways. Testosterone was not a primary endpoint in any published MT-II human trial [22].

**What does the research say about melanotan and erythropoietic protoporphyria?**
MT-I (afamelanotide/Scenesse) is the only approved analog. Phase 3 EPP trials: median 69.4 hours pain-free vs. 40.8 hours placebo (US study) [15]. EU approval 2014, FDA approval 2019. MT-II has not been studied in EPP.

## References

[1] Lan EL et al. Preformulation studies with melanotan-II. J Pharm Sci. 1994. PMID: 7983590
[2] Hadley ME, Dorr RT. Melanocortin peptide therapeutics. Peptides. 2006. PMID: 16412534
[3] Dorr RT et al. Evaluation of melanotan-II in a pilot phase-I clinical study. Life Sci. 1996. PMID: 8637402
[4] Hida T et al. Elucidation of Melanogenesis Cascade. Int J Mol Sci. 2020. PMID: 32854423
[5] Wessells H et al. Synthetic melanotropic peptide initiates erections. J Urol. 1998. PMID: 9679884
[6] Wessells H et al. Melanocortin receptor agonists, penile erection. Int J Impot Res. 2000. PMID: 11035391
[7] Wessells H et al. Effect of alpha-MSH analog on penile erection. Urology. 2000. PMID: 11018622
[8] Zhang Y et al. Intermittent MTII application evokes repeated anorexia. Peptides. 2010. PMID: 20034526
[9] Cote I et al. Activation of the central melanocortin system. Can J Physiol Pharmacol. 2017. PMID: 28051332
[10] Eliason NL et al. Melanotan-II microinjected in nucleus accumbens. Neuropeptides. 2022. PMID: 36155088
[11] Peters B et al. Melanotan II: a possible cause of renal infarction. CEN Case Rep. 2020. PMID: 31953620
[12] Nelson ME, Bryant SM. Melanotan II injection: rhabdomyolysis. Clin Toxicol. 2012. PMID: 23121206
[13] Hueso-Gabriel L et al. Eruptive dysplastic nevi following melanotan use. Actas Dermosifiliogr. 2012. PMID: 22425244
[14] Sivyer GW. Changes of melanocytic lesions induced by Melanotan. Dermatol Pract Concept. 2012. PMID: 23785612
[15] Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015. PMID: 26132941
[16] Biolcati G et al. Long-term observational study of afamelanotide. Br J Dermatol. 2015. PMID: 25494545
[19] Hadley ME, Dorr RT. Melanocortin peptide therapeutics (PT-141). Peptides. 2006. PMID: 16412534
[21] Ter Laak MP et al. Melanotan-II promotes peripheral nerve regeneration. Eur J Pharmacol. 2003. PMID: 12591111
[22] Raposinho PD et al. Melanotan-II reduces orexigenic effects of NPY. J Neuroendocrinol. 2003. PMID: 12535159
[23] Gilhooley E et al. Melanotan II User Experience. Dermatology. 2021. PMID: 34464955
[24] Bonchev A. Changes in Oral Mucosa Associated with Melanotan II. Life (Basel). 2026. PMID: 41752902
[25] Alsabbagh AY et al. Melanotan II nasal spray and oral mucosal malignant melanoma. Int J Oral Maxillofac Surg. 2025. PMID: 40210573
[26] Paiva L et al. Effect of Melanotan-II on Brain Fos and Oxytocin Neuronal Activity. J Neuroendocrinol. 2017. PMID: 28009464

---

A drill-down index of the peer-reviewed melanotan record — Phase I trials, preclinical mechanism studies, and documented adverse events, cited to the source.